11:27 AM EDT, 06/25/2024 (MT Newswires) -- Carisma Therapeutics ( CARM ) said Tuesday that the US Food and Drug Administration has granted fast track designation for CT-0525, an investigational drug to treat HER2-overexpressing solid tumors.

The company said it is enrolling participants with locally advanced unresectable or metastatic solid tumors overexpressing HER2 for a phase 1 trial and targets to report initial data by year-end.

The phase 1 trial, which initially consists of two dose escalation cohorts, will evaluate the safety, tolerability and manufacturing feasibility of CT-0525, according to Carisma.

Price: 1.14, Change: +0.01, Percent Change: +1.34